These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9731502)

  • 21. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
    Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
    Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.
    DeBenedette MA; Wen T; Bachmann MF; Ohashi PS; Barber BH; Stocking KL; Peschon JJ; Watts TH
    J Immunol; 1999 Nov; 163(9):4833-41. PubMed ID: 10528184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.
    von Herrath MG; Coon B; Lewicki H; Mazarguil H; Gairin JE; Oldstone MB
    J Immunol; 1998 Nov; 161(9):5087-96. PubMed ID: 9794447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W; He L; Cao X
    Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
    J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function.
    Sharma S; Stolina M; Lin Y; Gardner B; Miller PW; Kronenberg M; Dubinett SM
    J Immunol; 1999 Nov; 163(9):5020-8. PubMed ID: 10528207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of lewis lung carcinoma in mice.
    Savai R; Schermuly RT; Schneider M; Pullamsetti SS; Grimminger F; Seeger W; Banat GA
    J Immunother; 2006; 29(2):175-87. PubMed ID: 16531818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors.
    Gladow M; Uckert W; Blankenstein T
    Eur J Immunol; 2004 Jul; 34(7):1882-91. PubMed ID: 15214036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired anti-viral T cell responses due to expression of the Ly49A inhibitory receptor.
    Zajac AJ; Vance RE; Held W; Sourdive DJ; Altman JD; Raulet DH; Ahmed R
    J Immunol; 1999 Nov; 163(10):5526-34. PubMed ID: 10553080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
    Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
    Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity.
    Hermans IF; Ritchie DS; Yang J; Roberts JM; Ronchese F
    J Immunol; 2000 Mar; 164(6):3095-101. PubMed ID: 10706699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TCR vaccines for active immunotherapy of T cell malignancies.
    Okada CY; Wong CP; Denney DW; Levy R
    J Immunol; 1997 Dec; 159(11):5516-27. PubMed ID: 9548492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of cytotoxic lymphocytes obtained by in vitro immunization with syngeneic lymphoma cells on pluripotent hemopoietic cells].
    Voĭtenok NN; Mitskevich PB; Murzenok PP
    Biull Eksp Biol Med; 1985 May; 99(5):604-6. PubMed ID: 3873966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.
    Sarma S; Guo Y; Guilloux Y; Lee C; Bai XF; Liu Y
    J Exp Med; 1999 Mar; 189(5):811-20. PubMed ID: 10049945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals.
    von Hoegen P; Heicappell R; Griesbach A; Altevogt P; Schirrmacher V
    Invasion Metastasis; 1989; 9(2):117-33. PubMed ID: 2785093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T cells.
    Stärck L; Popp K; Pircher H; Uckert W
    J Immunol; 2014 Jan; 192(1):206-13. PubMed ID: 24293634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy.
    Matthews KE; Hermans IF; Roberts JM; Ching LM; Ronchese F
    Immunol Cell Biol; 2006 Aug; 84(4):383-9. PubMed ID: 16834573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An examination of tumor antigen loss in spontaneous metastases.
    Dennis JW; Donaghue TP; Kerbel RS
    Invasion Metastasis; 1981; 1(2):111-25. PubMed ID: 6985358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice.
    Otahal P; Schell TD; Hutchinson SC; Knowles BB; Tevethia SS
    J Immunol; 2006 Sep; 177(5):3089-99. PubMed ID: 16920946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-cell receptor diversity prevents T-cell lymphoma development.
    Newrzela S; Al-Ghaili N; Heinrich T; Petkova M; Hartmann S; Rengstl B; Kumar A; Jäck HM; Gerdes S; Roeder I; Hansmann ML; von Laer D
    Leukemia; 2012 Dec; 26(12):2499-507. PubMed ID: 22643706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.